Call for Speaker Proposals
第1届
Emerging Targeted Oncology Partnering Forum
-为了在癌治疗领域合作的论坛-
2月19日～20日
在特定的患者集体中，加深对促进癌进行分子机制的理解，已从以非特定多数人作为对象之诊断法和治疗法为主流的时代，急剧变化成重视个别化、缩小标的方法的时代。最近导入缩小利用低分子治疗药和高分子治疗药标的的治疗。然进行这种治疗时，要执行引进诊断（companion），判断哪个患者要实施什么样的治疗才是最适合的情况占大半。此外，可标的化的机制数亦增加。然大半因应这种标的的方法，才处于刚开始开发的阶段。此时期，刚加入开发新方法不久的企业，以及能从技术、遵守法规、促进销售等面支持新治疗法和诊断法开发的有力企业，建立合作关系就变得极为重要。此论坛的目的在于将正在开发癌新治疗法和诊断法的新兴企业、为寻求能实现个别化癌治疗方法新能力的制药公司、生物科技企业及诊断技术的企业链接起来。
Preliminary Program Advisory Board:
Dr. John Meduri, Strategic Planning & Business Development, BD Diagnostics
Dr. Andrea Lauber, Head, Transactions for Clinical Biomarkers & Pharmacodiagnostics Strategy, Alliances & Transactions, Bristol Myers Squibb
Dr. Rosanne Welcher, Vice President, Research & Development, DAKO
Mollie Roth, Chief Operating Officer, Diaceutics
Dr. Premal Shah, Director, Business Development, Genomic Health
Dr. Eric Lai, Senior Vice President, Research & Development, Gen-Probe
Dr. Steven Anderson, Chief Scientific Officer & Vice President, LabCorp
Dr. Jorge Leon, President, Leomics Consulting
Alan Carter, President, MDX Consulting
Dr. Brian DeChairo, Senior Director & Development Head, Medco Health Solutions
Dr. Thomas Li , Senior Director, Technology Management, Roche Diagnostics
Brian Atwood, Managing Director, Versant Ventures
Featured approaches will include, but are not limited to:
- Small Molecule Therapeutics
- Targeting Kinases
- Targeting HDAC
- Targeting VEGF and Angiogenic Factors
- Cancer Vaccines
- Monoclonal Antibody Therapeutics
- Targeting of Cancer Stem Cells
- Targeting of Cancer Cell Metabolism
- Other Novel Targeted Therapeutics
- Companion Diagnostics
- Cancer Biomarkers
